Australia markets closed

    -33.80 (-0.50%)

    -0.0008 (-0.11%)
  • ASX 200

    -34.80 (-0.52%)
  • OIL

    +0.41 (+0.41%)
  • GOLD

    -3.30 (-0.19%)

    +365.33 (+1.25%)
  • CMC Crypto 200

    -3.98 (-0.90%)

PYC Therapeutics Invited to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SAN DIEGO and PERTH, Australia, Sept. 15, 2021 /PRNewswire/ -- PYC Therapeutics (ASX: PYC), a biotechnology company combining two complementary platform technologies (selective drug delivery and precision drug design) to develop a new generation of RNA therapeutics to change the lives of patients with inherited diseases, today announced it will participate as one of a select group of companies at the upcoming Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, taking place virtually on September 20–23, 2021.

(PRNewsfoto/PYC Therapeutics)
(PRNewsfoto/PYC Therapeutics)

Sahm Nasseri, U.S. Chief Executive Officer of PYC, will present a corporate overview on Tuesday, September 21, 2021 at 4:35 p.m ET. Members of PYC's management team will also participate in one-on-one meetings with U.S biotech and life science investors.

A live webcast link of the Oppenheimer presentation will be available in the "Events" section of the Investor & Media Center page of the Company's website at A replay of the presentation will be archived on the Company's website following the conference.

About PYC Therapeutics
PYC Therapeutics (ASX: PYC) is a development-stage biotechnology company pioneering a new generation of RNA therapeutics that utilize PYC's proprietary library of naturally derived cell penetrating peptides to overcome the major challenges of current genetic medicines. PYC believes its PPMO (Peptide conjugated Phosphorodiamidate Morpholino Oligomer) technology enables a safer and more effective RNA therapeutic to address the underlying drivers of a range of genetic diseases for which no treatment solutions exist today. The Company is leveraging its leading-edge science to develop a pipeline of novel therapies including three preclinical stage programs focused on inherited eye diseases and preclinical discovery efforts focused on neurodegenerative diseases. PYC's discovery and laboratory operations are located in Australia, and the Company's preclinical, clinical, regulatory and corporate operations are based in San Diego, California. For more information, visit, or follow us on LinkedIn and Twitter.

Forward looking statements
Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

Deborah Elson/Matthew DeYoung
Argot Partners

Leo Vartorella
Argot Partners


View original content to download multimedia:

SOURCE PYC Therapeutics

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting